Responses to crizotinib in patients with ALK-positive lung adenocarcinoma who tested immunohistochemistry (IHC)-positive and fluorescence in situ hybridization (FISH)-negative
| Autor: | Junling Li, Wang Zheng, Lin Yang, Xinming Zhao, Yan Wang, Xinlin Mu, Dongmei Lin, Di Ma |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Male
0301 basic medicine Pathology Lung Neoplasms Time Factors Oncogene Proteins Fusion Pyridines Tyrosine-kinase inhibitor 0302 clinical medicine hemic and lymphatic diseases Anaplastic lymphoma kinase Anaplastic Lymphoma Kinase Precision Medicine In Situ Hybridization Fluorescence medicine.diagnostic_test ALK status Middle Aged Immunohistochemistry Treatment Outcome Oncology 030220 oncology & carcinogenesis Monoclonal Adenocarcinoma Female medicine.drug Adult China medicine.medical_specialty medicine.drug_class Adenocarcinoma of Lung Antineoplastic Agents 03 medical and health sciences Crizotinib Predictive Value of Tests Biomarkers Tumor medicine Humans Protein Kinase Inhibitors fluorescence in situ hybridization Aged business.industry Patient Selection Receptor Protein-Tyrosine Kinases Cancer medicine.disease 030104 developmental biology non-small-cell lung cancer Cancer research Pyrazoles Clinical Research Paper Tomography X-Ray Computed business Fluorescence in situ hybridization |
| Zdroj: | Oncotarget |
| ISSN: | 1949-2553 |
| Popis: | Although the Ventana immunohistochemistry (IHC) platform for detecting anaplastic lymphoma kinase gene (ALK) (D5F3) expression was recently approved by the US Food and Drugs Administration (FDA), fluorescence in situ hybridization (FISH) is still the “gold-standard” method recommended by the US National Comprehensive Cancer Network (NCCN) guideline for NSCLC. We evaluated 6 ALK-positive lung adenocarcinoma patients who tested Ventana IHC-positive and FISH-negative and assessed their clinical responses to the ALK tyrosine kinase inhibitor (TKI) crizotinib. Histologic and cytologic specimens from the 6 patients were stained with Ventana anti-ALK(D5F3) rabbit monoclonal primary antibody using the OptiView™ DAB IHC detection kit and OptiView™ amplification kit on a Ventana BenchMark XT processor. In addition, they were also tested by FISH, qRT-PCR, next-generation sequencing (NGS), and RNAscope ISH analysis. All patients received crizotinib treatment and their follow-up clinical data were recorded. The objective response rate achieved with crizotinib therapy was 66.7% (4/6 partial responses and 2/6 stable disease). One patient in whom a new fusion type (EML4->EXOC6B->ALK fusion) was identified obtained a partial response. These findings indicate that patients with ALK-positive lung adenocarcinoma who test Ventana IHC-positive and FISH-negative may still respond to crizotinib therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|